

12 February 2026

## ASX Announcement

# H1 FY26 Results Presentation: Registration Details

PolyNovo Limited H1 FY26 results presentation will be live streamed on Friday, 20 February at 2.00 pm AEDT. To access the webcast, shareholders will need to register prior to commencement of the presentation.

### To register

- Visit <https://event.choruscall.com/mediaframe/webcast.html?webcastid=H8e32Z7G>
- Once registered, attendees will receive a confirmation email with additional information about the event.

### Q&A:

- Shareholders can submit written questions:
  - prior to the webcast by emailing [investor@polynovo.com](mailto:investor@polynovo.com) or
  - live during the webcast via the webcast platform
- Analysts who cover the Company can dial in and ask questions live during the webcast
- We will endeavour to address all questions received during the update and/or the Q&A session.

This announcement has been authorised by PolyNovo Company Secretary, Jan Gielen.


### About PolyNovo<sup>®</sup>

**PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds.** Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners.

The proprietary NovoSorb<sup>®</sup> polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets.

Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth.

For more information see [polynovo.com](http://polynovo.com)



### About NovoSorb® Technology

**NovoSorb® is a proprietary biodegradable polymer platform designed to support tissue regeneration in complex wound care.** The unique characteristics of NovoSorb® provide several key advantages including excellent biocompatibility, control over physical properties, a programmable bio-resorption profile and can be produced in many formats including film, fibre, foam, and coatings.

**NovoSorb® BTM** is a synthetic dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. This innovative product was the first to be commercially available utilising NovoSorb® technology and is supported by a growing body of independent clinical evidence.

**NovoSorb® MTX** is PolyNovo's latest advanced wound care product; a fully synthetic dermal matrix, developed in response to surgeon demand for a dermal substitute without a temporising, sealing membrane. Since receiving FDA 510(k) clearance in 2022, NovoSorb® MTX has rapidly gained surgeon adoption and is emerging as a key driver of growth.

